Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2010

Open Access 01-12-2010 | Research article

Hypoxia and hypoglycaemia in Ewing's sarcoma and osteosarcoma: regulation and phenotypic effects of Hypoxia-Inducible Factor

Authors: Helen J Knowles, Karl-Ludwig Schaefer, Uta Dirksen, Nicholas A Athanasou

Published in: BMC Cancer | Issue 1/2010

Login to get access

Abstract

Background

Hypoxia regulates gene expression via the transcription factor HIF (Hypoxia-Inducible Factor). Little is known regarding HIF expression and function in primary bone sarcomas. We describe HIF expression and phenotypic effects of hypoxia, hypoglycaemia and HIF in Ewing's sarcoma and osteosarcoma.

Methods

HIF-1α and HIF-2α immunohistochemistry was performed on a Ewing's tumour tissue array. Ewing's sarcoma and osteosarcoma cell lines were assessed for HIF pathway induction by Western blot, luciferase assay and ELISA. Effects of hypoxia, hypoglycaemia and isoform-specific HIF siRNA were assessed on proliferation, apoptosis and migration.

Results

17/56 Ewing's tumours were HIF-1α-positive, 15 HIF-2α-positive and 10 positive for HIF-1α and HIF-2α. Expression of HIF-1α and cleaved caspase 3 localised to necrotic areas. Hypoxia induced HIF-1α and HIF-2α in Ewing's and osteosarcoma cell lines while hypoglycaemia specifically induced HIF-2α in Ewing's. Downstream transcription was HIF-1α-dependent in Ewing's sarcoma, but regulated by both isoforms in osteosarcoma. In both cell types hypoglycaemia reduced cellular proliferation by ≥ 45%, hypoxia increased apoptosis and HIF siRNA modulated hypoxic proliferation and migration.

Conclusions

Co-localisation of HIF-1α and necrosis in Ewing's sarcoma suggests a role for hypoxia and/or hypoglycaemia in in vivo induction of HIF. In vitro data implicates hypoxia as the primary HIF stimulus in both Ewing's and osteosarcoma, driving effects on proliferation and apoptosis. These results provide a foundation from which to advance understanding of HIF function in the pathobiology of primary bone sarcomas.
Appendix
Available only for authorised users
Literature
1.
Vaupel P, Mayer A: Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007, 26: 225-239. 10.1007/s10555-007-9055-1.CrossRefPubMed
2.
Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian YM, Masson N, Hamilton DL, Jaakkola P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ, Ratcliffe PJ: C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell. 2001, 107: 43-54. 10.1016/S0092-8674(01)00507-4.CrossRefPubMed
3.
Bruick RK, McKnight SL: A conserved family of prolyl-4-hydroxylases that modify HIF. Science. 2001, 294: 1337-1340. 10.1126/science.1066373.CrossRefPubMed
4.
Harris AL: Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer. 2002, 2: 38-47. 10.1038/nrc704.CrossRefPubMed
5.
Maynard MA, Ohh M: The role of hypoxia-inducible factors in cancer. Cell Mol Life Sci. 2007, 64: 2170-2180. 10.1007/s00018-007-7082-2.CrossRefPubMed
6.
Yang QC, Zeng BF, Dong Y, Shi ZM, Jiang ZM, Huang J: Overexpression of Hypoxia-Inducible Factor-1{alpha} in Human Osteosarcoma: Correlation with Clinicopathological Parameters and Survival Outcome. Jap J Clin Oncol. 2007, 37: 127-134. 10.1093/jjco/hyl137.CrossRef
7.
Mizobuchi H, Garcia-Castellano JM, Philip S, Healey JH, Gorlick R: Hypoxia markers in human osteosarcoma: An exploratory study. Clin Orthopaed Rel Res. 2008, 466: 2052-2059. 10.1007/s11999-008-0328-y.CrossRef
8.
Chen WL, Feng HJ, Li HG: Expression and significance of hypoxemia-inducible factor-1 alpha in osteosarcoma of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endodontol. 2008, 106: 254-257. 10.1016/j.tripleo.2008.01.029.CrossRef
9.
van der Schaft DW, Hillen F, Pauwels P, Kirschmann DA, Castermans K, Egbrink MG, Tran MG, Sciot R, Hauben E, Hogendoorn PC, Delattre O, Maxwell PH, Hendrix MJ, Griffioen AW: Tumor cell plasticity in Ewing sarcoma an alternative circulatory system stimulated by hypoxia. Cancer Res. 2005, 65: 11520-11528. 10.1158/0008-5472.CAN-05-2468.CrossRefPubMed
10.
Kubo T, Sugita T, Shimose S, Matsuo T, Arihiro K, Ochi M: Expression of hypoxia-inducible factor-1 alpha and its relationship to tumour angiogenesis and cell proliferation in cartilage tumours. J Bone Joint Surg-Br Vol. 2008, 90B: 364-370. 10.1302/0301-620X.90B3.19806.CrossRef
11.
Knowles HJ, Athanasou NA: Hypoxia-inducible factor is expressed in giant cell tumour of bone and mediates paracrine effects of hypoxia on monocyte-osteoclast differentiation via induction of VEGF. J Pathol. 2008, 215: 56-66. 10.1002/path.2319.CrossRefPubMed
12.
Holzer G, Obermair A, Koschat M, Preyer O, Kotz R, Trieb K: Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with malignant bone tumors. Med Pediat Oncol. 2001, 36: 601-604. 10.1002/mpo.1136.CrossRef
13.
Kreuter M, Paulussen M, Boeckeler J, Gerss J, Buerger H, Liebscher C, Kessler T, Jurgens H, Berdel WE, Mesters RM: Clinical significance of vascular endothelial growth factor - a expression in Ewing's sarcoma. Eur J Cancer. 2006, 42: 1904-1911. 10.1016/j.ejca.2006.01.063.CrossRefPubMed
14.
Kaya M, Wada T, Akatsuka T, Kawaguchi S, Nagoya S, Shindoh M, Higashino F, Mezawa F, Okada F, Ishii S: Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res. 2000, 6: 572-577.PubMed
15.
Kaya M, Wada T, Kawaguchi S, Nagoya S, Yamashita T, Abe Y, Hiraga H, Isu K, Shindoh M, Higashino F, Okada F, Tada M, Yamawaki S, Ishii S: Increased pre-therapeutic serum vascular endothelial growth factor in patients with early clinical relapse of osteosarcoma. Brit J Cancer. 2002, 86: 864-869. 10.1038/sj.bjc.6600201.CrossRefPubMedPubMedCentral
16.
Dunst J, Ahrens S, Paulussen M, Burdach S, Jurgens H: Prognostic impact of tumor perfusion in MR-imaging studies in Ewing tumors. Strahlenther Onkol. 2001, 177: 153-159.CrossRefPubMed
17.
Jenkin RD, Al-Fawaz I, Al-Shabanah M, Allam A, Ayas M, Khafaga Y, Memon M, Rifai S, Schultz H, Younge D: Localised Ewing Sarcoma/PNET of bone - Prognostic factors and international data comparison. Med Pediat Oncol. 2002, 39: 586-593. 10.1002/mpo.10212.CrossRef
18.
Kavalar R, Marinsek ZP, Jereb B, Cagran B, Golouh R: Prognostic value of CD99, CD117, p53 and bcl-2 in Ewing sarcoma family tumours. Eur J Oncol. 2007, 12: 243-253.
19.
Mayes PA, Campbell L, Ricci MS, Plastaras JP, Dicker DT, El-Deiry WS: Modulation of TRAIL-induced tumor cell apoptosis in a hypoxic environment. Cancer Biol Ther. 2005, 4: 1068-1074. 10.4161/cbt.4.10.2255.CrossRefPubMed
20.
Kim HH, Lee SE, Chung WJ, Choi Y, Kwack K, Kim SW, Kim MS, Park H, Lee ZH: Stabilization of hypoxia-inducible factor-1 alpha is involved in the hypoxic stimuli-induced expression of vascular endothelial growth factor in osteoblastic cells. Cytokine. 2002, 17: 14-27. 10.1006/cyto.2001.0985.CrossRefPubMed
21.
Doege K, Heine S, Jensen I, Jelkmann W, Metzen E: Inhibition of mitochondrial respiration elevates oxygen concentration but leaves regulation of hypoxia-inducible factor (HIF) intact. Blood. 2005, 106: 2311-2317. 10.1182/blood-2005-03-1138.CrossRefPubMed
22.
Akeno N, Czyzyk-Krzeska MF, Gross TS, Clemens TL: Hypoxia induces vascular endothelial growth factor gene transcription in human osteoblast-like cells through the hypoxia-inducible factor-2alpha. Endocrinol. 2001, 142: 959-962. 10.1210/en.142.2.959.
23.
Kilic M, Kasperczyk H, Fulda S, Debatin KM: Role of hypoxia inducible factor-1 alpha in modulation of apoptosis resistance. Oncogene. 2007, 26: 2027-2038. 10.1038/sj.onc.1210008.CrossRefPubMed
24.
Yeo EJ, Chun YS, Cho YS, Kim JH, Lee JC, Kim MS, Park JW: YGI: A potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst. 2003, 95: 516-525. 10.1093/jnci/95.7.516.CrossRefPubMed
25.
Guan H, Jia SF, Zhou Z, Stewart J, Kleinerman ES: Herceptin down-regulates HER-2/neu and vascular endothelial growth factor expression and enhances taxol-induced cytotoxicity of human Ewing's sarcoma cells in vitro and in vivo. Clin Cancer Res. 2005, 11: 2008-2017. 10.1158/1078-0432.CCR-04-0777.CrossRefPubMed
26.
Ottaviano L, Schaefer KL, Gajewski M, Huckenbeck W, Baldus S, Rogel U, Mackintosh C, de Alava E, Myklebost O, Kresse SH, Meza-Zepeda LA, Serra M, Cleton-Jansen AM, Hogendoorn PC, Buerger H, Aigner T, Gabbert HE, Poremba C: Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort. Genes Chromosomes Cancer. 49: 40-51. 10.1002/gcc.20717.
27.
Sowter HM, Raval RR, Moore JW, Ratcliffe PJ, Harris AL: Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia. Cancer Res. 2003, 63: 6130-6134.PubMed
28.
Raval RR, Lau KW, Tran MGB, Sowter HM, Mandriota SJ, Li JL, Pugh CW, Maxwell PH, Harris AL, Ratcliffe PJ: Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol. 2005, 25: 5675-5686. 10.1128/MCB.25.13.5675-5686.2005.CrossRefPubMedPubMedCentral
29.
Covello KL, Simon MC, Keith B: Targeted replacement of hypoxia-inducible factor-1alpha by a hypoxia-inducible factor-2alpha knock-in allele promotes tumor growth. Cancer Res. 2005, 65: 2277-2286. 10.1158/0008-5472.CAN-04-3246.CrossRefPubMed
30.
Qing GL, Simon MC: Hypoxia inducible factor-2 alpha: a critical mediator of aggressive tumor phenotypes. Curr Opin Genet Dev. 2009, 19: 60-66. 10.1016/j.gde.2008.12.001.CrossRefPubMedPubMedCentral
31.
Warnecke C, Weidemann A, Volke M, Schietke R, Wu XQ, Knaup KX, Hackenbeck T, Bernhardt W, Willam C, Eckardt KU, Wiesener MS: The specific contribution of hypoxia-inducible factor-2 alpha to hypoxic gene expression in vitro is limited and modulated by cell type-specific and exogenous factors. Exp Cell Res. 2008, 314: 2016-2027. 10.1016/j.yexcr.2008.03.003.CrossRefPubMed
32.
Warnecke C, Zaborowska Z, Kurreck J, Erdmann VA, Frei U, Wiesener M, Eckardt KU: Differentiating the functional role of hypoxia-inducible factor (HIF)-1 alpha and HIF-2 alpha (EPAS-1) by the use of RNA interference: erythropoietin is a HIF-2 alpha target gene in Hep3B and Kelly cells. Faseb J. 2004, 18: 1462-PubMed
33.
Mole DR, Blancher C, Copley RR, Pollard PJ, Gleadle JM, Ragoussis J, Ratcliffe PJ: Genome-wide Association of Hypoxia-inducible Factor (HIF)-1 alpha and HIF-2 alpha DNA Binding with Expression Profiling of Hypoxia-inducible Transcripts. J Biol Chem. 2009, 284: 16767-16775. 10.1074/jbc.M901790200.CrossRefPubMedPubMedCentral
34.
Batra S, Perelman N, Luck LR, Shimada H, Malik P: Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival. Lab Invest. 2003, 83: 1477-1487. 10.1097/01.LAB.0000090156.94795.48.CrossRefPubMed
35.
Nilsson H, Jogi A, Beckman S, Harris AL, Poellinger L, Pahlman S: HIF-2 alpha expression in human fetal paraganglia and neuroblastoma: relation to sympathetic differentiation glucose deficiency and hypoxia. Exp Cell Res. 2005, 303: 447-456. 10.1016/j.yexcr.2004.10.003.CrossRefPubMed
36.
Maltepe E, Schmidt JV, Baunoch D, Bradfield CA, Simon MC: Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein ARNT. Nature. 1997, 386: 403-407. 10.1038/386403a0.CrossRefPubMed
37.
Natsuizaka M, Ozasa M, Darmanin S, Miyamoto M, Kondo S, Kamada S, Shindoh M, Higashino F, Suhara W, Koide H, Aita K, Nakagawa K, Kondo T, Asaka M, Okada F, Kobayashi M: Synergistic up-regulation of Hexokinase-2, glucose transporters and angiogenic factors in pancreatic cancer cells by glucose deprivation and hypoxia. Exp Cell Res. 2007, 313: 3337-3348. 10.1016/j.yexcr.2007.06.013.CrossRefPubMed
38.
Vordermark D, Kraft P, Katzer A, Bolling T, Willner J, Flentje M: Glucose requirement for hypoxic accumulation of hypoxia-inducible factor-1 alpha (HIF-1 alpha). Cancer Lett. 2005, 230: 122-133. 10.1016/j.canlet.2004.12.040.CrossRefPubMed
39.
Kwon SJ, Lee YJ: Effect of low glutamine/glucose on hypoxia-induced elevation of hypoxia-inducible factor-1 alpha in human pancreatic cancer MiaPaCa-2 and human prostatic cancer DU-145 cells. Clin Cancer Res. 2005, 11: 4694-4700. 10.1158/1078-0432.CCR-04-2530.CrossRefPubMed
40.
Harada H, Itasaka S, Kizaka-Kondoh S, Shibuya K, Morinibu A, Shinomiya K, Hiraoka M: The Akt/mTOR Pathway Assures the Synthesis of HIF-1 alpha Protein in a Glucose- and Reoxygenation-dependent Manner in Irradiated Tumors. J Biol Chem. 2009, 284: 5332-5342. 10.1074/jbc.M806653200.CrossRefPubMed
41.
Kissane JM, Askin FB, Foulkes M, Stratton LB, Shirley SF: Ewing's sarcoma of bone: clinicopathologic aspects of 303 cases from the Intergroup Ewing's Sarcoma Study. Hum Pathol. 1983, 14: 773-779. 10.1016/S0046-8177(83)80300-1.CrossRefPubMed
42.
Araya R, Uehara T, Nomura Y: Hypoxia induces apoptosis in human neuroblastoma SK-N-MC cells by caspase activation accompanying cytochrome c release from mitochondria. FEBS letters. 1998, 439: 168-172. 10.1016/S0014-5793(98)01363-5.CrossRefPubMed
43.
Brusselmans K, Bono F, Maxwell P, Dor Y, Dewerchin M, Collen D, Herbert JM, Carmeliet P: Hypoxia-inducible factor-2 alpha (HIF-2 alpha) is involved in the apoptotic response to hypoglycemia but not to hypoxia. J Biol Chem. 2001, 276: 39192-39196. 10.1074/jbc.C100428200.CrossRefPubMed
44.
Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R, Maxwell P, Koch CJ, Ratcliffe P, Moons L, Jain RK, Collen D, Keshet E: Role of HIF-1 alpha or in hypoxia-mediated apoptosis cell proliferation and tumour angiogenesis. Nature. 1998, 394: 485-490. 10.1038/28867.CrossRefPubMed
45.
Halterman MW, Miller CC, Federoff HJ: Hypoxia-inducible factor-1 alpha mediates hypoxia-induced delayed neuronal death that involves p53. J Neurosci. 1999, 19: 6818-6824.PubMed
46.
Papandreou I, Krishna C, Kaper F, Cai DL, Giaccia AJ, Denko NC: Anoxia is necessary for tumor cell toxicity caused by a low-oxygen environment. Cancer Res. 2005, 65: 3171-3178.PubMed
47.
Brunelle JK, Shroff EH, Perlman H, Strasser A, Moraes CT, Flavell RA, Danial NN, Keith B, Thompson CB, Chandel NS: Loss of Mcl-1 protein and inhibition of electron transport chain together induce anoxic cell death. Mol Cell Biol. 2007, 27: 1222-1235. 10.1128/MCB.01535-06.CrossRefPubMed
48.
Kondo K, Kim WY, Lechpammer M, Kaelin WG: Inhibition of HIF2 alpha is sufficient to suppress pVHL-defective tumor growth. Plos Biol. 2003, 1: 439-444. 10.1371/journal.pbio.0000083.CrossRef
49.
Gordan JD, Bertout JA, Hu CJ, Diehl JA, Simon MC: HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell. 2007, 11: 335-347. 10.1016/j.ccr.2007.02.006.CrossRefPubMedPubMedCentral
50.
Koshiji M, Kageyama Y, Pete EA, Horikawa I, Barrett JC, Huang LE: HIF-1 alpha induces cell cycle arrest by functionally counteracting Myc. Embo J. 2004, 23: 1949-1956. 10.1038/sj.emboj.7600196.CrossRefPubMedPubMedCentral
51.
Imamura T, Kikuchi H, Herraiz MT, Park DY, Mizukami Y, Mino-Kenduson M, Lynch MP, Rueda BR, Benita Y, Xavier RJ, Chung DC: HIF-1 alpha and HIF-2 alpha have divergent roles in colon cancer. Int J Cancer. 2009, 124: 763-771. 10.1002/ijc.24032.CrossRefPubMedPubMedCentral
52.
Ben-Shoshan J, Schwartz S, Luboshits G, Maysel-Auslender S, Barzelay A, Polak-Charcon S, Tzahor E, Barshack I, Barak A, Levkovitch-Verbin H, Keren G, George J: Constitutive Expression of HIF-1 alpha and HIF-2 alpha in Bone Marrow Stromal Cells Differentially Promotes Their Proangiogenic Properties. Stem Cells. 2008, 26: 2634-2643. 10.1634/stemcells.2008-0369.CrossRefPubMed
53.
Yin DZ, Jia TH, Gong WM, Yu HY, Wooley PH, Mott MP, Yang SY: VEGF blockade decelerates the growth of a murine experimental osteosarcoma. Int J Oncol. 2008, 33: 253-259.PubMed
54.
Guan H, Zhou ZC, Wang H, Jia SF, Liu WB, Kleinerman ES: A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing's sarcoma growth in a xenograft mouse model. Clin Cancer Res. 2005, 11: 2662-2669. 10.1158/1078-0432.CCR-04-1206.CrossRefPubMed
Metadata
Title
Hypoxia and hypoglycaemia in Ewing's sarcoma and osteosarcoma: regulation and phenotypic effects of Hypoxia-Inducible Factor
Authors
Helen J Knowles
Karl-Ludwig Schaefer
Uta Dirksen
Nicholas A Athanasou
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2010
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-10-372

Other articles of this Issue 1/2010

BMC Cancer 1/2010 Go to the issue

Research article

Boron neutron capture therapy induces apoptosis of glioma cells through Bcl-2/Bax

Research article

Irradiation-induced telomerase activity and gastric cancer risk: a case-control analysis in a Chinese Han population

Research article

SHOX2 DNA Methylation is a Biomarker for the diagnosis of lung cancer based on bronchial aspirates

Research article

The influence of nativity and neighborhoods on breast cancer stage at diagnosis and survival among California Hispanic women

Research article

Pancreatic adenocarcinoma exerts systemic effects on the peripheral blood myeloid and plasmacytoid dendritic cells: an indicator of disease severity?

Research article

Glycogen Synthase Kinase-3 regulates multiple myeloma cell growth and bortezomib-induced cell death
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits